PDCD1 and non-small cell lung carcinoma: Since the Food and Drug Administration (FDA) first approved PD-1 inhibitors in 2016 for the treatment of non-small cell lung cancer (NSCLC), pembrolizumab-based immunotherapy has been become standard of care [3–5].